CareFusion said that the CLiO2 system noninvasively and continuously measures the oxygen level in a newborn’s blood using Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry technology to provide accurate and reliable oxygen saturation (SpO2) measurements, even under challenging clinical conditions.
The CLiO2 system processes blood oxygen saturation levels by a computer algorithm that then anticipates trends and modifies the amount of oxygen delivered. If necessary, adjustments can be made on a second to second basis, something not currently possible with manual control.
David Schlotterbeck, chairman and CEO at CareFusion, said: “We built the CLiO2 system to address a worldwide medical need to improve the way newborns are cared for in hospitals. We hope this system will help reduce complications associated with newborns needing mechanical ventilation and can free up time for clinicians to better care for some of their most vulnerable patients.”